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 70 
Abstract  71 
Leber inherited optic neuropathy (LHON) is characterized by subacute bilateral loss of central vision 72 
due to dysfunction and loss of retinal ganglion cells (RGCs). Comprehensive visual 73 
electrophysiological investigations (including pattern reversal visual evoked potentials, pattern 74 
electroretinography and the photopic negative response) performed on 13 patients with acute and 75 
chronic LHON indicate early impairment of RGC cell body function and severe axonal dysfunction. 76 
Temporal, spatial and chromatic psychophysical tests performed on 7 patients with acute LHON and 77 
4 patients with chronic LHON suggest severe involvement or loss of the midget, parasol and 78 
bistratified RGCs associated with all three principal visual pathways.  79 
  80 
Word count: 100 81 
 82 
 83 
 84 
 85 
 86 
87 
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 88 
1. Introduction 89 
Leber hereditary optic neuropathy (LHON) (OMIM 535000) is a primary mitochondrial DNA (mtDNA) 90 
disorder that presents with bilateral subacute loss of central vision (Nikoskelainen et al., 1996; Yu-91 
Wai-Man and Chinnery, 2000; Yu-Wai-Man et al., 2014). The majority of patients harbour one of 92 
three common mtDNA mutations (m.3460G>A in MTND1, m.11778G>A in MTND4and m.14484T>C 93 
in MTND6) that affect complex I subunits of the mitochondrial respiratory chain (Mackey et al., 94 
1995). Despite the universal cellular role of mitochondria, retinal ganglion cells (RGCs) within the 95 
papillomacular bundle are particularly particularly severely affected accounting for the characteristic 96 
dense central or caecocentral scotoma in this disorder. Although the underlying pathological process 97 
is still not fully defined, this tissue specificity has been ascribed to an increased vulnerability of RGCs 98 
to both disturbed mitochondrial energy metabolism and the increased formation of reactive oxygen 99 
species (Carelli et al., 2004a; Lin et al., 2012; Sadun et al., 2000; Levin 2015; Sadun et al., 2015). 100 
LHON shows maternal inheritance, but there is variable disease penetrance and a marked sex bias 101 
with about 50% of male carriers losing vision during their lifetime compared with about 10% of 102 
female carriers (Mackey et al., 1995). 103 
The histopathological observation of loss of the small calibre axons that constitute the 104 
papillomacular bundle was originally observed on histopathological sections of post mortem optic 105 
nerve samples obtained several decades after disease onset (Sadun et al., 1994; Kerrison et al., 106 
1995; Sadun et al., 2000). More recently, in vivo studies involving high-resolution optical coherence 107 
tomography (OCT) have revealed a major loss of the temporal peripapillary nerve fiber (RNFL) and 108 
macular RGC layers within 3 months of disease onset. Interestingly, pathological thinning within the 109 
macular RGC layer was an early sign that was already apparent in the presymptomatic phase 110 
(Barboni et al., 2005; Barboni et al., 2010; Akiyama et al., 2013; Zhang et al., 2014; Mizoguchi et al., 111 
2015; Balducci et al., 2015). Following disease conversion, swelling of the peripapillary RNFL spreads 112 
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circumferentially from the inferotemporal segment of the optic disc to involve the remaining 113 
quadrants, before RNFL atrophy becomes established within 3-9 months after the onset of visual 114 
loss. Hyperemia and fluctuating mild swelling of the prepapillary RNFL can also be seen in unaffected 115 
LHON carriers without visual loss or progression to full disease conversion (Nikoskelainen et al., 116 
1982).  117 
 The function of the papillomacular bundle may be assessed objectively using pattern 118 
reversal visual evoked potentials (PR-VEP) and pattern electroretinography (PERG).  Reported PR-119 
VEP abnormalities in LHON are consistently severe, but the utility of the PERG in LHON is more 120 
controversial and there are conflicting reports in the literature regarding the timing of responses and 121 
the sequence of losses (Nikoskelainen et al., 1977; Hrynchak and Spafford, 1994; Mashima et al., 122 
1997; Sharkawi et al., 2012; Ziccardi et al., 2013; Ziccardi et al., 2015; Jarc-Vidmar et al., 2015). The 123 
full-field photopic negative response (PhNR) has been used to assess generalised RGC function in 124 
glaucoma and other acquired optic neuropathies (Machida, 2012; Morny et al., 2015), but there are 125 
no published studies of PhNR in LHON. The applicability of PhNR as a potential objective functional 126 
index of RGC function in LHON therefore warrants further investigation. 127 
RGCs are classified into the three major subtypes of RGCs, namely midget, parasol and small 128 
bistratified ganglion cells, which are thought to contribute to the parvocellular, magnocellular and 129 
koniocellular pathways, respectively. These distinct RGC populations and their associated pathways 130 
can be tested by modifying standard psychophysical measures. In general, the processing of high 131 
spatial frequency information has been linked with the parvocellular pathway whereas high 132 
temporal frequency information is thought to be integrated by the magnocellular pathway. Red-133 
green processing and blue-yellow processing have been linked with the parvocellular and 134 
koniocellular pathways, respectively. Parallel processing in the retina and visual pathways have been 135 
the subject of several recent comprehensive reviews (e.g., Dowling, 1987; Wässle and Boycott, 1991; 136 
Rodieck, 1998; Lennie and Movshon, 2005; Lee, Martin and Grünert, 2010; Dacey, Crook, and 137 
Packer, 2014).  138 
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LHON is thought to mainly affect midget RGCs, which have the smallest calibre axons and 139 
are the predominant subtype within the papillomacular bundle, mediating visual information 140 
including high spatial frequencies and red-green chromaticity (Sadun et al., 1994; Hrynchak and 141 
Spafford, 1994; Kerrison et al., 1995; Sadun et al., 2000). In contrast, another melanopsin-expressing 142 
RGC subtype appears relatively preserved and this peculiarity likely accounts for the frequently 143 
preserved pupillary light reflexes, even in severely affected LHON patients (Kawasaki et al., 2010; La 144 
Morgia et al., 2010). One previous report indicated mild impairment of the magnocellular pathway in 145 
unaffected LHON carriers (Gualtieri et al., 2008), but there are no robust data regarding the 146 
involvement of the parasol and small bistratified RCG subtypes in LHON.  147 
In this study, we investigated the pattern of RGC dysfunction in a well-phenotyped cohort of 148 
LHON patients in both the acute and chronic phases of the disease by using a comprehensive visual 149 
electrophysiological and psychophysical assessment protocol. Our aim was, firstly, to characterise 150 
the electrophysiological responses to better define the phenotypic features of LHON and to establish 151 
the most appropriate methods for monitoring RGC function and disease progression objectively. 152 
Secondly, we used psychophysical tests of temporal, spatial and chromatic vision to investigate the 153 
relative involvement of distinct RGC populations in the pathophysiology of LHON. 154 
155 
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 156 
2. Methods 157 
2.1 Subjects 158 
This was a prospective case study of 12 affected patients (A1-A12) and 9 unaffected carriers (U1-U9) 159 
harboring one of the three common mtDNA LHON mutations (Table 1). In addition, retrospective 160 
visual electrophysiological data for 5 affected LHON patients (A13-A17) were retrieved from the 161 
hospital database of Moorfields Eye Hospital, London, UK. In total, there were 4 affected female and 162 
13 affected male patients. Affected LHON patients and unaffected LHON carriers in our cohort 163 
underwent an ophthalmological examination that included the following investigations as indicated 164 
in Table 1: best corrected visual acuity (BCVA) assessment using the Early Treatment Diabetic 165 
Retinopathy Study (ETDRS) chart; slit lamp examination; automated Humphrey visual field perimetry 166 
(Program 30-2, Humphrey Visual Field Analyzer, Model 750, Humphrey Instruments, San Leonardo, 167 
CA); and optical coherence tomography (OCT) imaging of the macula and the optic nerve head (see 168 
details below). 169 
The normal subjects for psychophysical tests were 15 individuals aged 17 to 78 years old at 170 
the time of testing with normal BCVA and normal color vision as assessed by standard color vision 171 
tests. Only 12 of the normal subjects had their L-cone temporal contrast sensitivities measured. 172 
Written informed consent was obtained from all subjects or their guardians. The study was approved 173 
by the local ethics committees at Moorfields Eye Hospital and University College London and it 174 
conformed to the standards of the Declaration of Helsinki. 175 
 176 
177 
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 179 
Table 1. Clinical characteristics of the recruited LHON cohort and the timing of investigations in 180 
relation to disease onset. 181 
S
u
b
je
ct
s 
Age (y) 
Sex 
Genotype  
BCVA logMAR* 
 
Visual field defect MD 
(dB) 
 
Time from LHON onset at study 
(months) 
OCT 
Electro-
physiology 
Psycho-
physics 
RE LE RE LE RE LE RE LE RE/LE 
 Affected LHON patients  
A1 42 M m.11778G>A 1.4 1.5* -32.26 -28.63* 15 15 16 16 9 LE 
A2 18 M m.11778G>A 1.6 1.5* -32.07 -32.89* NP 18 18 10 LE 
A3 19 F m.3460G>A 1.9* 1.9 -34.39* -34.46 0.7 0 17 16 10 RE 
A4 21 M m.11778G>A 2.0 2.0* -34.18 -33.79* 15 19 15 19 9 LE 
A5 17 M m.11778G>A 2.2* 2.28 -34.48* -34.31 10 10 14 15 10 RE 
A6 15 M m.11778G>A 1.6* 1.7 -29.11* -28.56 6 6 8 8 6 RE 
A7 22 M m.11778G>A 0.7 0.8* -19.36 -15.10* 32 32 
NP 
36 LE 
A8 33 M m.11778G>A 2.1* 2.1 -33.30* -33.23 34 28 34 RE 
A9 24 M m.14484T>C 1.3* 1.3 -12.01* -12.63 20 23 23 RE 
A10 51 F m.11778G>A 1.6* 1.6 -24.23* -27.51 40 40 40 RE 
A11 23 M m.11778G>A 1.8* 2.3 -32.11* -29.76 4 5 4 RE 
A12 50 F m.11778G>A 1.9 1.9 -30.54 -29.86 6 0 10 3 
NP 
A13 22 M m.11778G>A 0.8 1.0 
NP 
 
0 1 0 1 
A14 36 M m.14484T>C 1.3 1.0 98 98 5 5 
A15 7 M m.11778G>A 0.6 2.0 140 140 27 27 
A16 7 F m.3460G>A 1.7 1.5 
NP 
2 2 
A17  59M m.3700G>A 1.9 1.9 20 20 
 Unaffected LHON carriers 
U1 44 F m.11778G>A 0* 0 -10.83* -18.08 
P NP P 
U2 46 M m.11778G>A 0* 0 -2.57* -2.42 
U3 52 F m.3460G>A 0.1* 0 -0.97* -1.43 
U4 47 F m.11778G>A -0.1* -0.1 -3.51* -3.17 
U5 50 F m.14484T>C 0.1* 0 0.18* 0.26 
U6 50 F m.11778G>A -0.1* 0.1 -2.59* -0.24 
U7 41 F m.3460G>A 0* 0 0.06* -0.99 
U8 60 F m.3460G>A -0.1* 0 1.11* 0.22 
U9 46 F m.11778G>A 0* 0 -1.81* -1.64 
Abbreviations: BCVA, best corrected visual acuity: DOA, dominant optic atrophy; F, female; LE, left 182 
eye; LHON, Leber hereditary optic atrophy; M, male; NP, not performed; P, performed; RE, right eye. 183 
* BCVA and MD of the eye used for the monocular psychophysics tests are indicated by asterisks.  184 
185 
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 186 
2.2 Optical coherence tomography (OCT) imaging 187 
The SpectralisTM platform (Heidelberg Engineering Ltd., Heidelberg, Germany) was used for SD-OCT 188 
imaging of the macula and the optic nerve head. Automated segmentation and thickness analyses 189 
were performed for perifoveal volumetric retinal B-scans using the Heidelberg Engineering 190 
segmentation tool, included in the Spectralis Glaucoma Module software (version 6.0). Of the 10 191 
retinal layers that were automatically defined and manually confirmed, the following thickness 192 
values were recorded from the four sectors of the inner ring (between 1 to 3 mm diameter) of the 193 
nine macular ETDRS subfields as described elsewhere (Majander et al., 2016): (i) retina, (ii) retinal 194 
nerve fiber layer (RNFL), (iii) combined GCL and inner plexiform layer (IPL), (iv) inner nuclear layer 195 
(INL), (v) outer plexiform layer (OPL), (vi) combined OPL and outer nuclear layer (ONL), and (v) inner 196 
retina. The thickness of the outer retinal layers was calculated by subtracting the thickness of the 197 
inner retinal layers from the total retinal thickness. Normative data was generated from SD-OCT 198 
images of 48 healthy eyes of 48 subjects (Majander et al., 2016). For peripapillary RNFL 199 
measurement a 3.5-mm-diameter circular scan centered on the optic disc was used and the data for 200 
six sectors were collected.  201 
 202 
2.3 Electrophysiology investigations 203 
Twelve subjects underwent electrophysiological testing including pattern reversal and flash visual 204 
evoked potential (PVEP; FVEP) and pattern electroretinography (PERG), incorporating the standards 205 
of the International Society for Clinical Electrophysiology of Vision (ISCEV; Odom et al. 2010, Bach et 206 
al. 2013). Pattern ERGs were recorded to a 0.8- degree check size using both a standard 207 
checkerboard field (12 x 15 degrees) and additionally to a large field (24 x 30 degrees; LF PERG; 208 
Lenassi et al., 2012).  The full-field photopic negative response (PhNR) was additionally recorded in 7 209 
cases using diffuse red flash stimulation (640nm) at 5 flash strengths (0.5, 1.0, 2.0, 5.0 and 10.0 210 
11 
 
cd.s.m-2), superimposed on a blue background (450nm; 2.25 cd.m-2). Gold foil electrodes were used 211 
and the results compared to normative data.  212 
 213 
2.4 Psychophysical investigations 214 
2.4.1  L- and S-cone Critical Flicker Fusion and L-cone temporal contrast sensitivity  215 
L- and S-cone temporal acuities (critiĐal ﬂiĐker fusioŶ, CFFͿ aŶd L-cone temporal contrast sensitivity 216 
functions (TCSFs) were measured using a Maxwellian-view optical system described in more detail 217 
elsewhere (Stockman et al., 2005 and 2014a).  Predominantly L-cone or S-cone stimuli were used for 218 
the CFF measurements. The L-cone stimulus was produced by flickering a 650-nm circular target of 219 
4˚ visual angle in diameter superimposed in the center of a steady 481-nm circular background field 220 
of ϵ˚ diaŵeter. The background radiance was fixed at 8.3 log10 quanta s-1 deg-2 and the target 221 
radiance was varied in steps from 6.5 to 10.5 log10 quanta s-1 deg-2. The S-cone stimulus was 222 
produced by flickering a 440-nm circular target also of 4˚ diameter superimposed in the center of a 223 
620-nm circular background field of 9˚ diaŵeter. The 620-nm background radiance was fixed at 8.3 224 
log10 quanta s-1 deg-2 and the 440-nm target radiance was varied in steps from 6.5 to 10 log10 quanta 225 
s-1 deg-2.  The 650-nm target and 481-nm background were also used for the L-cone TCSF 226 
measurements with the time-averaged mean radiance of the 650-nm target fixed at 10.6 log10 227 
quanta s-1 deg-2.  Before each run the subjects were light-adapted to the background and target for at 228 
least 2 minutes. The observers viewed the stimuli monocularly with their preferred eye (see Table 2) 229 
and interacted with the computer by means of an 8-button keypad. Each experiment was repeated 230 
2-3 times on the same day. The method of adjustment was used. In the CFF measurements, 231 
observers varied the frequency of the 650 or 440-nm target, which was sinusoidally-flickering with a 232 
contrast of 92%, to find the frequency at each target radiance at which the flicker until the flicker 233 
just disappeared. In the TCSF measurements, observers varied the contrast of the sinusoidally-234 
12 
 
flickering 650-nm target to establish the contrast at each target frequency at which the flicker 235 
disappeared. Details of these measurements have been given elsewhere (Stockman et al., 2014a). 236 
 237 
2.4.2 Achromatic spatial contrast sensitivity function (SCSF) 238 
Achromatic spatial contrast sensitivity (SCSF) was measured as a function of spatial frequency. The 239 
target stimuli were generated on a gamma-corrected Sony Trinitron monitor (Model GDM F520) 240 
with a resolution of 1600 x 1200 pixels and produced at a frame rate of 85-Hz. The monitor was 241 
driven by a DataPixx video processor (VPixx Technologies Inc., Saint-Bruno, QC, Canada). The full 242 
screen subtended a visual angle of 39˚ x 29˚ at a test distance of 0.57 m. The experiments were 243 
performed at a constant mean luminance of 44.57 cd/m2 as measured by a ColorCal calibration 244 
device (Cambridge Research Systems Ltd., Rochester, UK). The stimuli were horizontally-orientated 245 
Gabor patterns with spatial frequencies ranging from 0.25 to 16 cycles per degree (cpd) and with a 246 
spatial Gaussian window with a standard deviation of 6˚. The target was presented for 500 ms, 247 
preceded and followed by 100 ms cosine-windowed onsets and offsets. The order of presentation 248 
was from low to high spatial frequency. Thresholds were measured using a staircase procedure. , 249 
Observers indicated whether or not they could detect the spatial variation in the Gabor pattern 250 
using a 2-button keypad.  251 
Stimulus contrast was defined as (Lmax- Lmin)/(Lmax + Lmin), where Lmax and Lmin are the 252 
maximum and minimum luminances in the Gabor pattern, respectively. Contrast was adjusted 253 
according to a one-up-one-down staircase procedure with a variable step-size. The step-size was 0.3 254 
log10 units for the first five reversals (changes in the direction of the staircase), after which it was 255 
reduced to 0.2 log10 units for two more reversals and then finally to 0.1 log10 unit for the last four 256 
reversals. A single run required a total of 9 reversals, with the contrast ͞threshold͟ takeŶ as the 257 
average of the last six reversals. Contrast sensitivity is the reciprocal of the contrast threshold. The 258 
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SCSF measurements lasted approximately 20 minutes for each observer. The stimuli were viewed 259 
binocularly with natural pupils and appropriate correction if needed. 260 
 261 
2.4.3 Chromatic discrimination 262 
Chromatic discrimination was tested using the so-called trivector test procedure implemented as 263 
part of the Cambridge Color Test (CCT), v1.5, (Cambridge Research Systems Ltd., Rochester, UK). The 264 
test was performed using a second gamma-corrected Sony FD Trinitron color monitor (Model GDM-265 
F500R) connected to a VSG 2/5 visual stimulus generator (Cambridge Research Systems, Rochester, 266 
UK) with 800 by 600 pixel resolution. The CRT phosphors measured iŶ CIE ϭϵϳϲ u’, v’ ĐhroŵatiĐitǇ 267 
coordinates (or CIE 1931 x, y coordinates) using ColorCal photometer (Cambridge Research System) 268 
were: red phosphor ;RͿ u’=Ϭ.ϰϭϲ; v’=Ϭ.ϱϮϮ ;ǆ=Ϭ.ϲϭϬ, Ǉ=Ϭ.ϯϰϬͿ; greeŶ phosphor ;GͿ u’=Ϭ.117; 269 
v’=Ϭ.ϱϱϵ ;ǆ=Ϭ.ϮϴϬ, Ǉ=Ϭ.ϱϵϱͿ; ďlue phosphor ;BͿ u’=Ϭ.ϭϱϵ; v’=Ϭ.ϭϳϳ ;ǆ=Ϭ.ϭϰϮ, Ǉ=Ϭ.ϬϳϬͿ. The visual 270 
stimuli ĐoŶsisted of LaŶdolt ͞C͟ targets that varied in orientation presented on a background of 271 
neutral chromaticity (CIE 1976 coordiŶates u’= Ϭ.ϭϵϳϳ, v’=Ϭ.ϰϲϴϵͿ. The ďaĐkgrouŶd aŶd the target 272 
were made up of small disks of variable size and luminance (ten equal steps between 8.0 and 18.0 273 
cd.m2). The circles making up the Landolt C were varied in chromaticity to find the threshold for 274 
correctly discriminating the orientation of the Landolt C. The chromaticity was varied separately 275 
along the three color directions that are invisible to observers lacking L-, M- or S-cones; that is, the 276 
protan, deutan and tritan vector directions, respectively. 277 
The test conditions were modified for observers with reduced visual acuity. Instead of the 278 
viewing distance being set so that the LaŶdolt ͞C͟ opeŶiŶg suďteŶded ϭ° of visual aŶgle, the viewing 279 
distance was reduced to 62.6 cm so that the opening subtended 5° of visual angle. Two (A7, A9) of 280 
the 11 affected LHON carriers, and one patient A6 after spontaneous recovery, were able to perform 281 
the CCT test at this viewing distance. Another 5 patients were able to perform the test at a viewing 282 
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distance of 5 to 10 cm that enabled recognition of the orientation of the gap despite their central 283 
scotomatas. Thresholds were measured along the protan, deutan, and tritan confusion lines. The 284 
upper limit for target saturation was increased to 1600 × 10−4 u’v’ uŶits aŶd the Ŷuŵďer of steps 285 
increased from 6 to 10 in order to maintain the standard unit difference between the steps. The 286 
time allowed for each subject to respond was increased from the standard 8 s to 20 s. The test was 287 
then run using a standard descending psychophysical staircase procedure with six reversals. 288 
Observers were instructed to respond to the gap position (four-alternative forced choice) by means 289 
of a 4-button keypad. The test was performed binocularly with appropriate near corrections if 290 
needed. Six of the affected LHON carriers repeated the CCT test 6 to 12 months after their first visit. 291 
 292 
2.5 Statistical analyses 293 
Mann-Whitney U independent samples test was used for comparison of distribution of continuous 294 
variables in LHON and normal observers. “pearŵaŶ’s raŶk Đorrelation test was used for the analysis 295 
of statistical dependence between the variables. 296 
 297 
3. Results 298 
 299 
3.1 The acute phase of LHON is characterised by rapid loss of RGCs 300 
Macular SD-OCT revealed selective loss of the GCL-IPL complex thickness (50% of the normal) within 301 
the first few months of disease onset in LHON as shown in the supplementary Table S1 and Figure 1. 302 
This occurred in parallel with loss of the temporal peripapillary RNFL thickness (Spearman rho=0.628, 303 
p=0.002), whereas progression of RNFL thinning in the nasal sectors was less steep.  The INL was 304 
slightly, but significantly thicker in the affected LHON carriers compared with controls or the 305 
unaffected LHON carriers.  306 
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 308 
 309 
1 COLUMN WIDTH 310 
Figure 1. Optical coherence tomography data. Macular ganglion cell – inner plexiform layer complex 311 
(GCL-IPL) and peripapillary retinal nerve fibre layer (RNFL) thicknesses of 22 eyes have been 312 
presented as percentages of the normal mean and plotted as a function of time from LHON onset in 313 
each eye. The data have been shown for temporal (T), nasal (N) and combined supero- and 314 
inferotemporal (TS and TI) sectors of peripapillary RNFL. Generalized additive model (GAM) fits to 315 
data are indicated by the colour coded lines. 316 
 317 
 318 
3.1 Visual electrophysiology:  pattern responses were more severely affected than photopic 319 
negative ERG responses 320 
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The age of the patients at the time of electrophysiological testing ranged from 7.5 to 59.0 years 321 
(mean = 26.6 years; SD = 16.7 years). The duration of symptoms ranged from 0 to 27 months (mean 322 
12.5 months). Visual acuity was severely impaired in all cases (range = 1.3 logMAR to perception of 323 
light). Characteristic electrophysiology waveforms for affected LHON carriers are shown in Figure 2. 324 
Photopic negative responses were attenuated at all stimulus strengths (see corresponding plots in 325 
Figure 2c and 2d; orange circles). Pattern reversal VEPs were undetectable and flash VEPs were 326 
grossly abnormal. Pattern ERG P50 is of short peak time and the waveforms had a low N95:P50 ratio, 327 
in keeping with severe optic nerve/retinal ganglion cell dysfunction bilaterally.  328 
 329 
 330 
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 331 
Figure 2. Photopic negative responses from the right (a) and left (b) eyes of a patient with LHON (A3). 332 
For comparison, representative normal recordings over a range of flash strengths (0.5-10.0 unit) have 333 
been provided (c). Pattern reversal VEPs, flash VEPs and pattern ERGs are shown for the right (d) and 334 
left (e) eyes of Patient A3 compared with representative normal recordings (f). The patient’s 335 
recordings have been superimposed for all the parameters tested to demonstrate reproducibility.   336 
 337 
Pattern reversal VEPs were undetectable in 20 of 24 eyes and were delayed in 4 eyes of 4 338 
subjects with detectable responses (peak time 121-142ms; upper limit of normal 115ms); amplitudes 339 
in 2 of the eyes with a delayed VEP were within the normal range (>4µV). Flash VEPs were 340 
undetectable in 5 eyes of 3 subjects (all with undetectable pattern VEP), were delayed (P2> 140ms) 341 
in 5 eyes, and were present but subnormal (<5µV) in 20 eyes. Flash VEPs were normal in 3 eyes of 2 342 
subjects including one of the youngest individuals (age 7.5 years).  The severity of pattern and flash 343 
VEP abnormality did not significantly correlate either with age or duration of symptoms.  344 
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Pattern ERG P50 to a standard stimulus (field size 12˚ x 15˚) was of abnormally short peak 345 
time (<45.5ms) in 19 of 21 eyes (Figure 3a PERG). P50 was of normal amplitude in most, mildly 346 
subnormal (<2.0µV) in 4 eyes of 4 patients (1.5-1.9µV) and of borderline amplitude (2.0µV) in a 347 
further 2 eyes (Figure 3b PERG); P50 was of shortened peak time in all 6 eyes with a borderline or 348 
mildly subnormal amplitude. The N95:P50 amplitude ratio was subnormal (<1.1) in 17 of 19 eyes 349 
(0.75-1.0) and at the lower limit of normal (ratio = 1.1) in a further 2 eyes (mean and median ratio of 350 
all cases 1.0; SD 0.1; Figure 3c PERG). PERGs were technically poor in 5 eyes of 4 cases due to 351 
variable fixation (N=1); pupil dilation (N=1) or physiological noise and those eyes were excluded from 352 
analysis. PERG to a doubled stimulus field (24˚ x 30˚) were obtained in 11 patients including 4 eyes in 353 
which the standard field PERG was excluded. Data were compared with a normative data set 354 
obtained using the same large field stimulus. Sixteen of 22 eyes were of abnormally short peak time 355 
(<46.5ms; Figure 3d PERG) and these included 4 patients with additional bilateral P50 reduction 356 
(1.9µV-2.7µV; normal>3.9µV). The N95:P50 ratio was subnormal in 8, borderline in 10 and normal in 357 
5 eyes (Figure 3e PERG).  There was no significant correlation between pattern ERG parameters and 358 
age or duration of symptoms.      359 
International-standard full-field ERGs revealed no clinically significant abnormality in the 7 360 
individuals tested. PhNRs were recorded from 14 eyes of 7 cases, including 5 individuals that did not 361 
undergo standard full-field ERGs. The ratios of PhNR/b-wave ratios were within the normal range in 362 
1 eye at all 5 flash intensities; in others the ratio was subnormal to one flash strength (N= 2 eyes), 363 
two (N=3 eyes), three (N= 1 eye), four (N=4 eyes) or 5 flash strengths (N=3 eyes) (Figure 4 PhNR). 364 
The mean magnitude of reduction of subnormal responses was 13% (range 1.5-23%) compared with 365 
the lower limit of normal. Forty percent of responses showed no abnormality (Figure 4c and 4d).  366 
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 369 
Figure 3. Pattern ERG data. Pattern ERG parameters were obtained to a standard (12˚ x15˚; a-c) and 370 
large (24 x 30 degrees; d-f) checkerboard stimulus field for right and left eyes (RE; LE). Broken lines 371 
show the limits of normality defined as the minimum/maximum amplitude or peak time in a healthy 372 
cohort of subjects +/- the reference interval (maximum normal value-minimum normal value). 373 
Pattern ERG peak times and/or the N95:P50 ratio were abnormal in all the cases. Large field pattern 374 
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ERG parameters were abnormal in most cases, including those in which PERG to the smaller field was 375 
excluded. The P50 amplitude of the pattern ERG was normal or near-normal in most cases, indicating 376 
good fixation despite of poor visual acuity.        377 
 378 
 379 
 380 
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 382 
Figure 4. Photopic negative response (PhNR) data. Mean photopic negative responses (a) and the 383 
mean PhNR/b-wave ratio (b) were recorded in 7 individuals with LHON and compared with normal 384 
values at 5 flash strengths. The solid line and error bars show the mean normal values and 2 385 
standard deviations from the mean. Broken lines show the limits of normality defined as the 386 
minimum amplitude in the normal cohort minus the 5% of the reference interval (maximum normal 387 
value-minimum normal value). Ratios from each individual are shown for right (RE; c) and left (LE; d) 388 
eyes. Sixty percent of responses were just outside the limits of normality (see text for details).     389 
 390 
 391 
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3.2 Visual Psychophysics 394 
 395 
3.2.1 L-cone temporal functions were severely compromised in LHON 396 
The data for L-cone cff (temporal acuity) are presented in Figure 5 and are summarized in the 397 
supplementary Table S2. In the normal observers (grey triangles), flicker was first seen at a target 398 
radiance of 6.6 log10 quanta s-1 deg-2. The cff then grew linearly with log radiance over about 3 log10 399 
units with a slope of 9.2 Hz per log10 unit (see upper blue line in the lower panel) until reaching  a 400 
plateau near 40 Hz (Stockman et al. 2014a). The linear relationship between cff and log radiance is 401 
known as the Ferry-Porter law (Ferry, 1892; Porter, 1902). Eight of the 11 affected LHON carriers 402 
were able to detect L-cone flicker, but the mean radiance of 9.6 log10 quanta s-1deg-2 at which flicker 403 
was first seen was 30 times higher than that for normal observers (Table S2). Three patients could 404 
detect flicker only at the highest target radiances. LHON patients thus required higher radiances to 405 
detect flicker than normal subjects and their cffs showed severe losses reaching a mean plateau of 406 
only 12 Hz, 28 Hz less than normal subjects. The lowest radiance at which unaffected LHON carriers 407 
first detected flicker was slightly higher than that for normal subjects (Table S2). Three carriers (U2, 408 
U6, U9) had significantly shallower Ferry-Porter slopes than normal and only three carriers (U1, U4, 409 
U8) had cffs that reached the normal plateau level of 40 Hz. The majority of the LHON carriers 410 
showed some loss of cff. Patient A6 experienced spontaneous recovery of BCVA from 1.6 logMAR to 411 
0.1 logMAR between 6 to 18 months after LHON onset. His cff improved, but only marginally (A6 F, 412 
yellow squares). 413 
Figure 6 shows the L-cone temporal contrast sensitivity data. The mean L-cone TCSF for 414 
normal subjects peaks in sensitivity near 8 Hz and falls off in sensitivity at both low and high 415 
temporal frequencies (Stockman et al. 2014a and 2014b; Ripamonti et al. 2014). Only patients A3, 416 
A7 and A9 of the affected carriers were able to perform the test and showed a mean sensitivity loss 417 
of 1.0 log10 unit. Unaffected LHON carriers had normal L-cone temporal modulation sensitivities but 418 
were unable to make settings at the highest temporal frequencies, consistent with their lower cffs. 419 
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 422 
Figure 5. L-cone critical flicker fusion. L-cone critical flicker frequencies (cff) were measured on a 423 
481–nm background of 8.26 log10 quanta s-1deg-2 and plotted as a function of the mean log10 424 
radiance of a 650-nm flickering target for the affected (A) and unaffected (B) LHON carriers. The 425 
mean cff data for 15 normal observers are represented by the grey triangles in all panels. The yellow 426 
squares (A6 F) indicate follow-up data for Patient A6, which were obtained after spontaneous 427 
recovery of best corrected visual acuity from 1.6 logMAR to 0.1 logMAR in the right eye. (C) Mean L-428 
cone cff data for all unaffected LHON carriers (yellow circles)were  compared with the mean normal 429 
data (grey triangles). The best-fitting Ferry-Porter slopes are indicated by the blue lines. The error 430 
bars represent ± 1 SEM either between runs for the individual patients or between observers for the 431 
mean data. 432 
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 434 
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Figure 6. Log10 L-cone temporal contrast sensitivity. Log10 L-cone TCSFs were measured using a 436 
sinusoidally-modulated 650-nm target with a time-averaged mean radiance of 10.28 log10 quanta s-1 437 
deg-2 superimposed on a 481-nm background of 8.29 log10 quanta s-1 deg-2 plotted as a function 438 
temporal frequency (logarithmic axis) for three affected LHON carriers (A3, A7, A9) (pink, blue and 439 
green triangles, respectively) and for the mean of 9 unaffected LHON carriers (yellow triangles). The 440 
mean TCSFs for 12 normal observers have been shown as grey triangles. The error bars represent ± 1 441 
SEM either between runs for the individual patients or between subjects for the mean data. The 442 
mean difference in log sensitivity between each affected or the mean of unaffected LHON carrier and 443 
normal subjects are shown in the lower part of each panel (circles). 444 
 445 
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3.2.2 S-cone temporal function was unmeasurable in most LHON patients and reduced in the 447 
unaffected m.3460G>A carriers 448 
In the normal subjects, flicker was first seen at a target radiance of about 6.5 log10 quanta s-1deg-2. 449 
Thereafter, the cff grows linearly with log radiance with a slope of 7.3 Hz per log10 unit, consistent 450 
with the Ferry-Porter law, until reaching a plateau at 9.0 log10 quanta s-1deg-2 (see Figure 7 and the 451 
supplementary Table S3). The rise after 9.9 log10 quanta s-1deg-2 is due to M-cone intrusion - the M-452 
cones become more sensitive than S-cones at high radiances and thus mediate flicker detection 453 
(Stockman et al. 1998 and 2014a).     454 
Only two affected LHON carriers (A7, A9) were able to detect any 440-nm flicker, and all 455 
showed severely impaired temporal acuity. S-cone cff was relatively normal for the unaffected 456 
carriers of the m. 11778G>A and the m. 14484T>C mutations, who first saw flicker at 07.10±0.06 457 
(mean±1 SEM) log10 quanta s-1deg-2, and exhibited a Ferry-Porter slope of 7.97±0.39 Hz per decade 458 
(mean±1 SEM) and a cff plateau frequency of 22.94±0.57 Hz (mean±1 SEM). In contrast, S-cone cff 459 
for the three carriers harboring the m.3460G>A mutation was compromised: those subjects first saw 460 
flicker at a radiance of 8.06±0.51 log10 quanta s-1deg-2, and exhibited a shallow Ferry-Porter slope of 461 
5.03±1.05 Hz per log10 unit, the cff reached a plateau frequency of 12.61±3.80 Hz. One carrier of the 462 
three with the m.3460G>A mutation could detect flicker only at the highest radiances, but was 463 
within normal limits for the tritan measurements in the CCT (see below).464 
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Figure 7. S-cone critical flicker frequencies 467 
(cff). This parameter was measured on a a 9° 468 
620 –nm background of 11.41 log10 quanta s-469 
1deg-2 and plotted as a function of the time-470 
averaged mean log10 radiance of a 440-nm 471 
flickering target for each affected (A) and 472 
unaffected (B) LHON carrier (colored symbols).  473 
The mean cff data for 15 normal subjects are 474 
shown by the grey triangles in all panels. (C). 475 
Mean S-cone cff data for all unaffected LHON 476 
carriers (yellow circles) compared with the 477 
mean normal data (grey triangle). The best-478 
fitting Ferry-Porter slopes are indicated by the 479 
blue lines (C). The error bars represent ± 1 480 
SEM either between runs for the individual 481 
patients, or between subjects for the mean 482 
data. 483 
484 
485 
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 486 
3.2.3 Achromatic spatial contrast sensitivity function (SCSF) was unmeasurable in most LHON 487 
patients and mildly subnormal in the unaffected carriers 488 
The mean achromatic spatial contrast sensitivity function for normal subjects is shown as inverted 489 
grey triangles in each of the three panels of supplementary Figure S1.  The function is band-pass in 490 
shape peaking at 2 cpd and falling off in sensitivity at lower and higher spatial frequencies 491 
characteristic of other SCSFs measured at moderate and high intensities (Robson, 1966; van Nes and 492 
Bouman, 1967).  Only two (A7 and A9) of the 11 affected LHON carriers could perform this test. Both 493 
patients showed a loss of contrast sensitivity that increased with frequency. In the unaffected LHON 494 
carriers, the achromatic SCSF was normal at the lowest spatial frequency but showed increasing loss 495 
as spatial frequency increased.496 
497 
3.2.4 Chromatic discrimination was severely affected in LHON 498 
Figure 8A shows the vector lengths of the three confusion lines (protan, deutan, and tritan) of the 499 
Cambridge Color Test in 10−4 u’v’ units (the CIE 1976 u’v’ color space). The longer the vector length 500 
the more saturated the color had to be for the orientation of the gap in the Landolt C to be 501 
discriminated. The maximum vector lengths were 1600 10−4 u’v’ units (the CIE 1976 u’v’ color space). 502 
The vector lengths in the normal observers were comparable to those previously reported using 503 
standard targets with 1 degree gaps: 45.1±1.0 for protan, 43.3±0.8 for deutan and 51.5±1.3 for tritan 504 
in 10−4 u’v’ units (the CIE 1976 u’v’ color space) [mean±SEM] (Paramei and Oakley 2014).  Altogether, 505 
8 affected LHON carriers could discriminate the gap in the Landolt C, most viewed the CRT screen 506 
from only 5 to 10 cm Their vector thresholds along the protan and the deutan axes on their first 507 
tests were 25.8±2.6 (mean±SEM) and 25.4±2.8 times higher, respectively, than controls whereas 508 
along the tritan axes the vectors were only 5.1±0.7 times higher. Figure 8B shows the vector lengths 509 
of the successive tests made on six affected LHON carriers. Three affected carriers (A1, A3, A6), 510 
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initially studied 6 to 9 months after LHON onset, showed recovery of color discrimination, mainly 511 
along protan and deutan axes. Chromatic discrimination in unaffected LHON carriers was only 512 
marginally subnormal along all chromatic axes with high normal vector lengths. Affected observers 513 
therefore show a general loss along all three axes. 514 
 515 
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 517 
 518 
Figure 8. The Trivector Cambridge color 519 
test. (A) Box plots of the logarithmic vector 520 
lengths along the protan, deutan and tritan 521 
confusion lines expressed in 10-4 u’v’ units 522 
(defined by the CIE 19ϳϲ u’v’ color space) 523 
for the affected (1, n=8) and unaffected (2, 524 
n=9) LHON carriers, and for normal 525 
observers (3, n=15), showing median, 526 
range, inter-quartile range and outliers for 527 
all groups. (B) Changes in the vector lengths 528 
along the protan, deutan and tritan 529 
confusion lines have been expressed as 10-4 530 
u’v’ units for successive measurements of 6 531 
affected LHON carriers and plotted as a 532 
function of time from disease onset.533 
534 
535 
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4. Discussion 536 
Our comprehensive electrophysiological and psychophysical study of patients with acute and chronic 537 
LHON highlights the marked extent of RGC dysfunction in this classical mitochondrial optic 538 
neuropathy.. Our study also indicates the utility of the standard transient pattern ERG technique in 539 
patients with LHON, with the recordings revealing severe central RGC dysfunction in all the patients 540 
tested, irrespective of visual acuity, age or the duration of symptoms. Detailed psychophysical data 541 
demonstrated loss of visual function in affected LHON carriers across a range of parameters, 542 
including achromatic spatial and L-cone temporal contrast sensitivity, L- and S-cone acuity, and 543 
chromatic discrimination. These findings are consistent with substantial losses of the principal RGC 544 
subtypes associated with each of the three major retinal pathways. Furthermore, with the exception 545 
of L-cone TCSF, unaffected LHON carriers also showed subclinical abnormalities in all the 546 
psychophysical measures that were evaluated.   547 
 A number of studies have reported abnormal cortical PR-VEPs responses in acute LHON, 548 
(Nikoskelainen et al., 1977; Hrynchak and Spafford, 1994; Mashima et al., 1997; Sharkawi et al., 549 
2012; Ziccardi et al., 2013). Our PR-VEP results are consistent with these previous observations and 550 
the early involvement of the papillomacular bundle in this mitochondrial optic nerve disorder. The 551 
PERG reflects central retinal function and has two major components; the positive P50 and negative 552 
N95 (Holder, 1987). The N95 component arises in RGCs whereas approximately 30% of the P50 553 
component originates in more anterior retinal structures (Holder, 1987, 2001; Ryan and Arden, 554 
1988; Viswanathan et al., 2000). P50 is widely used to assess macular function whereas reduction in 555 
the N95:P50 ratio with preservation of P50 amplitude or shortening of P50 peak time suggests RGC 556 
dysfunction (Holder, 2001). However, reports of PERG findings in LHON have been contradictory 557 
(Sharkawi et al., 2012; Ziccardi et al., 2013; Jarc-Vidmar et al., 2015). Some studies of LHON have 558 
used surface electrodes and rapidly alternating stimuli to elicit steady-state PERG recordings (Lam et 559 
al., 2010; 2014) but the signal:noise ratio for surface recordings is lower than for corneal recordings 560 
and abnormal amplitude reduction does not distinguish macular from retinal ganglion cell 561 
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dysfunction. Our study found consistent PERG abnormalities with shortened P50 peak time and 562 
reduced N95:P50 ratio in patients with acute LHON. Furthermore, P50 amplitude was preserved, 563 
consistent with adequate fixation despite the poor visual acuity and largely excluding a macular 564 
cause for the PR-VEP abnormality.  565 
The photopic negative response (PhNR) component of the full-field electroretinogram is 566 
severely reduced in primates treated with tetrodotoxin and in experimental models of glaucoma, in 567 
keeping with a possible RGC origin (Viswanathan et al., 1999). The PhNR has also been shown to be 568 
attenuated in experimental and clinical studies of glaucoma and in other forms of optic neuropathies 569 
(Viswanathan et al., 1999; Gotoh et al., 2004; Sustar et al., 2009; North et al., 2010; Preiser et al. 570 
2013; Machida, 2012; Morny et al., 2015). The majority of affected LHON patients in our study had 571 
responses near the limits of normal, with a substantial subgroup (40%) being within normal limits. 572 
There is no published data describing PhNRs in LHON, but mildly abnormal or borderline reductions 573 
in the PhNR have similarly been reported in dominant optic atrophy (Miyata et al., 2004). It is 574 
notable that both these mitochondrial optic neuropathies predominantly affect the papillomacular 575 
bundle with relative sparing of RGC axons in the retinal periphery (Johnston et al. 1979; Kerrison et 576 
al. 1995; Kjer et al. 1983; Sadun et al. 1994; Sadun et al. 2000). It should be noted that the full-field 577 
PhNR provides a measure of global RGC function and it could therefore be less sensitive in detecting 578 
focal RGC loss or dysfunction compared with the pattern ERG, which arises largely in central macular 579 
RGCs.  Other methods such as focal PhNRs, involving flash stimulation of the central macular area, 580 
could potentially offer better sensitivity compared with full-field photopic negative responses, but 581 
with the disadvantage of generating comparatively smaller signals. These findings are pertinent to 582 
clinical trials of future therapeutic interventions, since an undetectable VEP cannot be used to 583 
monitor safety and PERG could prove the objective test of choice to monitor function of the most 584 
affected RGCs.   585 
The international standard VEP and PERG stimuli involve high contrast checkerboard reversal 586 
stimuli that are suprathreshold, whereas psychophysics enables measurement of detection 587 
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threshold. Affected LHON carriers in our study had impaired chromatic resolution in the protan and 588 
deutan axes. Their achromatic spatial sensitivity was also severely compromised. Only the two least 589 
affected patients (A7 and A9) were capable of performing the achromatic spatial CSF measurements, 590 
but even then, steep sensitivity losses with increasing spatial frequency were evident. These findings 591 
are consistent with the severe loss of the midget RGCs and the small calibre RGC axons found in post 592 
mortem histological studies (Sadun et al. 1994; Kerrison et al. 1995; Sadun et al. 2000). The majority 593 
of LHON patients in our study were able to detect a flickering long-wavelength light at high 594 
luminance levels, but with markedly reduced temporal resolution, in keeping with a severe deficit of 595 
magnocellular function. This previously unreported observation is pathologically relevant as it 596 
implies that the loss of parasol RGC function is also present in acute LHON, which is consistent with 597 
the LGN pathology reported in end-stage disease (Rizzo et al., 2012). Previous studies that have 598 
assessed the koniocellular pathway in LHON have been limited to color vision tests (Nikoskelainen et 599 
al., 1977). Only the least severely affected patients (A7 and A9) in our study were able to detect 600 
flickering short-wavelength light and additional tritan deficits in the CCT tests suggested severe 601 
koniocellular involvement. The smaller proportional loss found along the tritan axis compared with 602 
the protan and deutan axes in the CCT test of affected LHON carriers is of doubtful clinical 603 
significance, since the unusually close viewing distances adopted by 5 of the observers might have 604 
selectively reduced the tritan thresholds due to rod intrusion, retinal inhomogeneities or scatter. In 605 
addition, melanopsin-expressing RGCs, which are relatively preserved in LHON (Kawasaki et al., 606 
2010; La Morgia et al., 2010), are preferentially sensitive to short-wavelength light (Lucas et al., 607 
2014) and, in theory, may also contribute to blue color discrimination.608 
 Previous studies on asymptomatic LHON carriers harboring the m.11778A>G mutation have 609 
reported subclinical visual impairment involving both the parvocellular and the magnocellular 610 
pathways as revealed by subtle chromatic and luminance contrast sensitivity deficits and impaired 611 
temporal processing (Ventura et al., 2005, Sadun et al., 2006, Ventura et al., 2007, Gualtieri et al., 612 
2008, Mateus et al., 2015).  Our study cohort included unaffected carriers with the m.3460A>G and 613 
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m.14484T>C LHON mutations, in addition to m.11778A>G. Our data indicate that all three common 614 
mtDNA LHON mutations significantly impair achromatic spatial contrast sensitivity worst for higher 615 
spatial frequencies. The chromatic thresholds along all three confusion lines showed mild losses 616 
compared with normals highlighting dysfunction of the parvocellular pathway and confirming a 617 
previous report using similar methods (Mateus et al., 2015). The majority of LHON carriers also 618 
showed abnormalities of the long-wavelength temporal visual acuity, but with relatively minimal loss 619 
on the L-cone TCSF measurements. These parvocelluar and magnocellular related losses were 620 
present with all three common mtDNA LHON mutations. Unlike the long-wavelength sensitive 621 
temporal visual acuity, impairment of the short-wavelength temporal acuity was limited to the three 622 
unrelated unaffected carriers harboring the m.3460A>G mutation. 623 
In conclusion, our study highlights the extent and severity of diffuse and focal 624 
electrophysiological measures of RGC dysfunction in LHON.  PERG abnormalities in LHON are largely 625 
independent of age and can be elicited in patients with severely impaired visual acuity. Furthermore, 626 
psychophysical tests of achromatic and chromatic visual function suggest severe involvement or loss 627 
of midget, parasol and bistratified RGCs. These findings are highly relevant for the design of future 628 
clinical trials aimed at assessing therapeutic interventions and the viability of specific RGC 629 
subpopulations in patients affected with LHON.  630 
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Supplementary data 830 
 831 
Table S1. Results of the macular and optic nerve head optical coherence tomography imaging. 832 
Retinal layer 
 
 
Layer thickness (µm) (mean±SD) 
 
Affected LHON 
(n=26 eyes) 
P * 
Unaffected 
LHON 
(n=18 eyes) 
Control 
(n=48 eyes) 
Macula     
Retina 306.3 ± 24.8 <0.001 349.0± 8.5 340.8 ± 13.3 
RNFL 19.2 ± 2.8 <0.001 24.8 ± 1.1 24.2 ± 2.1 
GCL-IPL 47.1 ± 14.6 <0.001 94.9 ± 3.4 93.5 ± 7.8 
INL 45.1 ± 4.7 <0.001 39.2 ± 2.3 39.6 ± 3.5 
OPL 33.0 ± 8.2 0.955 34.9 ± 4.7 32.3 ± 4.0 
OPL-ONL 110.9 ± 10.0 <0.001 107.4 ± 8.1 102.0 ± 8.6 
Outer retina 83.9 ± 3.4 0.002 82.9 ± 2.6 81.5 ± 2.7 
Peripapillary RNFL     
Inferotemporal 83.2 ± 47.3  152.4 ± 18.6 147** 
Temporal 33.4 ± 17.2  72.7 ± 2.5 78** 
Superotemporal 73.5 ± 46.0  122.3 ± 20.4 138** 
Superonasal 77.1 ± 35.2  111.4 ± 30.8 102** 
Nasal 54.0 ± 21.1  83.3 ± 13.7 72** 
Inferonasal 79.7 ± 35.0  126.4 ± 26.4 108** 
Average 66.8 ± 30.0  111.4 ± 12.4 108** 
 833 
Abbreviations: GCL-IPL, ganglion cell layer - inner plexiform layer complex; INL, inner nuclear layer; 834 
LHON, Leber hereditary optic neuropathy; OPL, outer plexiform layer; OPL-ONL, outer plexiform 835 
layer - outer nuclear layer complex; RNFL, retinal nerve fiber layer.   836 
* Mann-Whitney U Test 837 
** Heidelberg OCT normative mean 838 
839 
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Table S2. L-cone critical flicker fusion variables.  840 
Observer 
L-cone 
The lowest radiance 
(log10 quanta s-1deg-2) 
Ferry-Porter slope 
Per decade                R2 
Frequency  (Hz) 
at 8.5 log10 quanta 
s-1deg-2 radiance 
Plateau frequency 
(Hz) at 10.3-10.6 
log10 quanta 
s-1deg-2 radiance 
Normal 
mean±SE 6.65±0.06 9.16±0.35 0.998 27.90±0.91 40.18±0.88 
LHON      
A1 10.00 0.295 0.017 ND 11.60 
A2 8.99 2.873 0.933 ND 13.00 
A3 9.71 4.594 0.931 ND 6.78 
A4 10.63 ND ND ND 8.92 
A6 10.37 ND ND ND 16.00 
A7 8.05 2.914 0.762 ND 19.67 
A9 8.45 10.847 0.896 ND 21.84 
A10 10.94 ND ND ND 0.67 
A11      
LHON 
mean±SE 
9.64±0.43 4.30±1.59 0.71±0.18  12.31±2.84 
Mann-Whitney 
U test, p <0.001 <0.001   <0.001 
Carrier      
U1 6.89 8.62 0.99 26.08 41.89 
U2 7.46 5.37 0.97 19.32 29.11 
U3 7.21 7.85 0.99 17.02 33.17 
U4 5.42 9.24 0.92 24.13 37.22 
U5 7.21 8.20 0.94 21.34 34.80 
U6 7.16 6.55 0.93 18.83 30.72 
U7 7.43 9.30 0.99 19.07 28.89 
U8 6.84 8.00 0.99 27.21 39.56 
U9 7.18 7.17 0.95 19.48 32.89 
All carriers 
Mean±SE 6.98±0.19 7.81±0.43 0.96±0.01 21.39±1.19 34.25±1.43 
Mann-Whitney 
U test, p 0.004 0.035*  0.001* 0.004* 
Abbreviation: LHON, Leber hereditary optic neuropathy; ND, not determined. 841 
 842 
843 
41 
 
Table S3. S-cone critical flicker fusion variables. 844 
Observer 
S-cone 
The lowest radiance 
(log10 quanta s-1deg-2) 
Ferry-Porter slope 
  Per decade               R2 
Frequency  (Hz)  
at 8.5 log10 quanta  
s-1deg-2 radiance 
Plateau frequency 
(Hz) at 9.2-9.4 
log10 quanta  
s-1deg-2 radiance 
Normal  6.77±0.09 7.28±0.29 0.998 18.99±0.89 23.88±0.98 
Affected LHON      
A7 8.13 2.20 0.8219 ND 10.44 
A9 8.14 0.1074 0.055 ND 7.63 
All affected  8.14±0.00 4.30±1.59   9.04±0.53 
Unaffected      
U1 7.44 10.12 0.99 20.50 26.50 
U2 7.11 7.27 0.91 18.80 22.25 
U3 9.31 2.57 0.70 1.06 3.39 
U4 7.05 9.66 0.95 16.07 22.17 
U5 7.18 6.14 0.98 17.15 22.33 
U6 6.89 6.30 0.94 17.93 21.11 
U7 7.44 6.97 0.98 14.62 18.33 
U8 7.42 5.64 0.98 10.33 16.11 
U9 TC 6.91 6.39 0.91 15.86 23.28 
All unaffected 7.42±0.23 6.78±0.74 0.95±0.01 14.70±1.95 19.50±2.11 
Mann-Whitney 
U test, p 0.001* 0.411  0.055 0.049 
Abbreviation: LHON, Leber hereditary optic neuropathy; ND, not determined. 845 
846 
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 847 
 848 
Figure S1. Achromatic spatial contrast sensitivity functions. CSFs expressed as log10 sensitivity as a 849 
function of spatial frequency (cycles per degree, cpd – logarithmic scale) are shown for two affected 850 
LHON carriers (A7, A9) (blue triangles), for the mean of the 9 unaffected LHON carriers (yellow 851 
triangles) and for normal controls (inverted grey triangles). The difference in sensitivity between 852 
LHON carriers and normal is also indicated in each panel by colored circles. The symbols and error 853 
bars represent the mean ± 1 SEM across normal observers, repeated runs of individual LHON 854 
patients or across 9 unaffected LHON carriers. 855 
 856 
